Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Pendulum Therapeutics Inc. has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 4 distinct examiners and 3 distinct art units. The 4 pending office actions are spread such that each of the 4 distinct examiners is responsible for an action. This distribution indicates that no single examiner has a dominant role in the current prosecution of the portfolio.
IANNUZO, NATALIE NMN is the busiest examiner with 1 busiest examiner pending action. The 3 distinct art units suggest that the actions cover a range of biotechnological and pharmaceutical sub-specialties. This variety in art units means the company must address different examination criteria across its pending applications. Because each of the actions is with a different examiner, the company faces unique perspectives during the current prosecution cycle. This decentralized approach can lead to a portfolio tested against the standards of multiple examiners and art units.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §102 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| IANNUZO, NATALIE NMN | 1 | 12.2% | +71.4% |
| CRUM, MARY ABOU NADER | 1 | 39.2% | +63.7% |
| EIX, EMILY FAY | 1 | 45.7% | +76.0% |
| SPANGLER, JOSEPH RANKIN | 1 | 40.8% | +70.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569805 | Compositions Comprising Microbes and Methods of Use and Making Thereof | CRUM, MARY ABOU NADER | 47d |
| 18847148 | Novel Microbial Composition and Methods of Use Thereof | IANNUZO, NATALIE NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17604284 | MICROBIAL COMPOSITIONS AND METHODS FOR GREATER TOLERABILITY AND PROLONGED SHELF LIFE | SPANGLER, JOSEPH RANKIN | 104d overdue |
| 18569805 | Compositions Comprising Microbes and Methods of Use and Making Thereof | CRUM, MARY ABOU NADER | 47d |
| 18847148 | Novel Microbial Composition and Methods of Use Thereof | IANNUZO, NATALIE NMN | — |
| 17787880 | Compositions Comprising Microbes and Methods of Use and Making Thereof | EIX, EMILY FAY | — |
| Art Unit | Apps |
|---|---|
| 1653 | 2 |
| 1657 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18847148 | Novel Microbial Composition and Methods of Use Thereof | IANNUZO, NATALIE NMN | 1653 | §102§103§112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18569805 | Compositions Comprising Microbes and Methods of Use and Making Thereof | CRUM, MARY ABOU NADER | 1657 | §102§112Other | Non-Final OA | 47d | Pending | Dec 13, 2023 |
| 17787880 | Compositions Comprising Microbes and Methods of Use and Making Thereof | EIX, EMILY FAY | 1653 | §102Other | Final Rejection | — | Pending | Jun 21, 2022 |
| 17604284 | MICROBIAL COMPOSITIONS AND METHODS FOR GREATER TOLERABILITY AND PROLONGED SHELF LIFE | SPANGLER, JOSEPH RANKIN | 1656 | §103Other | Final Rejection | 104d overdue | Pending | Oct 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPendulum Therapeutics Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Natalie Nmn Iannuzo has the most, with 1 of Pendulum Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
